AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Feb 19, 2021
31289_dirs_2021-02-18_ef7fac36-27e9-417f-a33e-78698d80810a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-15
Reporting Person: FOEHR MATTHEW W (President and COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-15 | Common Stock | F | 641 | $172.46 | Disposed | 167557 | Direct |
| 2021-02-15 | Common Stock | F | 1235 | $172.46 | Disposed | 166322 | Direct |
| 2021-02-15 | Common Stock | F | 1222 | $172.46 | Disposed | 165100 | Direct |
Footnotes
F1: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018.
F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F3: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
Regulatory Filings
2026
Apr 27
Annual Report
2026
Apr 21